image
Healthcare - Biotechnology - NASDAQ - US
$ 0.76
-12.2 %
$ 70.7 M
Market Cap
-0.46
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 8, 2025.

The intrinsic value of one CRBU stock under the worst case scenario is HIDDEN Compared to the current market price of 0.76 USD, Caribou Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on May, 8, 2025.

The intrinsic value of one CRBU stock under the base case scenario is HIDDEN Compared to the current market price of 0.76 USD, Caribou Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on May, 8, 2025.

The intrinsic value of one CRBU stock under the best case scenario is HIDDEN Compared to the current market price of 0.76 USD, Caribou Biosciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CRBU

image
$2.4$2.4$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8$0.6$0.615 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
9.99 M REVENUE
-71.01%
-167 M OPERATING INCOME
-43.56%
-149 M NET INCOME
-46.08%
-138 M OPERATING CASH FLOW
-48.14%
86.6 M INVESTING CASH FLOW
227.02%
16.7 M FINANCING CASH FLOW
-89.16%
2.08 M REVENUE
2.62%
-38.9 M OPERATING INCOME
-1.67%
-35.5 M NET INCOME
-2.32%
-35.5 M OPERATING CASH FLOW
-8.60%
15.9 M INVESTING CASH FLOW
-39.93%
3.86 M FINANCING CASH FLOW
1483.20%
Balance Sheet Caribou Biosciences, Inc.
image
Current Assets 219 M
Cash & Short-Term Investments 210 M
Receivables 3.25 M
Other Current Assets 6.59 M
Non-Current Assets 93.9 M
Long-Term Investments 49.1 M
PP&E 39.3 M
Other Non-Current Assets 5.52 M
66.88 %15.68 %12.54 %Total Assets$313.3m
Current Liabilities 30.7 M
Accounts Payable 2.48 M
Short-Term Debt 0
Other Current Liabilities 28.2 M
Non-Current Liabilities 29.7 M
Long-Term Debt 0
Other Non-Current Liabilities 29.7 M
4.10 %46.68 %49.22 %Total Liabilities$60.4m
EFFICIENCY
Earnings Waterfall Caribou Biosciences, Inc.
image
Revenue 9.99 M
Cost Of Revenue 3.93 M
Gross Profit 6.07 M
Operating Expenses 177 M
Operating Income -167 M
Other Expenses -17.5 M
Net Income -149 M
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)10m(4m)6m(177m)(167m)18m(149m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
60.71% GROSS MARGIN
60.71%
-1667.16% OPERATING MARGIN
-1667.16%
-1491.95% NET MARGIN
-1491.95%
-58.95% ROE
-58.95%
-47.59% ROA
-47.59%
-58.94% ROIC
-58.94%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Caribou Biosciences, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)202020202021202120222022202320232024202420252025
Net Income -149 M
Depreciation & Amortization 3.93 M
Capital Expenditures -4.88 M
Stock-Based Compensation 16.7 M
Change in Working Capital -5.11 M
Others -9.97 M
Free Cash Flow -143 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Caribou Biosciences, Inc.
image
Wall Street analysts predict an average 1-year price target for CRBU of $3 , with forecasts ranging from a low of $3 to a high of $3 .
CRBU Lowest Price Target Wall Street Target
3 USD 294.74%
CRBU Average Price Target Wall Street Target
3 USD 294.74%
CRBU Highest Price Target Wall Street Target
3 USD 294.74%
Price
Max Price Target
Min Price Target
Average Price Target
44333322221111Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Caribou Biosciences, Inc.
image
Sold
0-3 MONTHS
14.4 K USD 3
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
20.4 K USD 1
0-3 MONTHS
24.7 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference BERKELEY, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 13th at 2:35 PM PDT. globenewswire.com - 2 weeks ago
Will Caribou Biosciences, Inc. (CRBU) Report Negative Q1 Earnings? What You Should Know Caribou Biosciences (CRBU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 3 weeks ago
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs -- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company's cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 now expected to be disclosed in  H2 2025 -- globenewswire.com - 3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Connect NEW YORK, NY / ACCESS Newswire / April 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU. accessnewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Shareholders to Learn More About the Investigation NEW YORK, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU. accessnewswire.com - 1 month ago
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU. accessnewswire.com - 1 month ago
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU. accessnewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Investors to Connect NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU. accessnewswire.com - 1 month ago
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation NEW YORK, NY / ACCESS Newswire / March 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU. accessnewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Reach Out NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU. accessnewswire.com - 2 months ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Connect NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU. accessnewswire.com - 2 months ago
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation NEW YORK, NY / ACCESS Newswire / March 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU. accessnewswire.com - 2 months ago
8. Profile Summary

Caribou Biosciences, Inc. CRBU

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 70.7 M
Dividend Yield 0.00%
Description Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Contact 2929 7th Street, Berkeley, CA, 94710 https://cariboubio.com
IPO Date July 23, 2021
Employees 147
Officers Ms. Barbara G. McClung Esq., J.D. Chief Legal Officer & Corporate Secretary Mr. Ryan Fischesser Interim Principal Accounting Officer & Controller Ms. Amy Figueroa C.F.A. Vice President of Investor Relations & Corporate Communications Ms. Ruhi A. Khan M.B.A. Chief Business Officer Mr. Timothy P. Kelly M.B.A. Chief Technology Officer Mr. Sriram Ryali M.B.A. Chief Financial Officer Dr. Steven B. Kanner Ph.D. Chief Scientific Officer Dr. Rachel E. Haurwitz Ph.D. Co-Founder, Chief Executive Officer, President & Director Mr. Daniel Poon Vice President of Operations & Information Technology Ms. Reigin Zawadzki Chief People Officer